Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited ('the Company') is scheduled to be held on Friday, February 11, 2022 inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021 as required under Regulation 33 of the Listing Regulations. Further, in continuation to our intimation dated December 31, 2021, and pursuant to Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in the securities of the Company is closed from January 01, 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2021. Kindly take the above on records.
04-02-2022

Sequent Scientific names Rajaram Narayanan as MD, CEO for five years

Narayanan replaces Manish Gupta who has put in his papers
15-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dear Sir / Madam, We enclose herewith a copy of Press Release titled 'SeQuent Scientific Appoints Pharmaceutical Industry Leader Rajaram Narayanan as Managing Director and CEO' being issued by the Company. You are requested to take the same on record
14-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Change in Directorate

Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), we wish to inform you that the Board o Directors of the Company has taken on record/approved the following changes in the composition of the Board of Directors at its meeting held on January 14, 2022: Name of Director Resignation/Appointment: Mr. Manish Gupta (DIN: 06805265) Resigned as a Managing Director and Chief Executive Officer (MD & CEO) of the Company with effect from April 10, 2022. Mr. Rajaram Narayanan (DIN: 02977405) Appointed as MD & CEO of the Company for a period of 5 years, with effect from April 11, 2022. The appointment is subject to the approval of shareholders of the Company, which shall be sought separately.
14-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the composition of the Board of Directors at its meeting held on January 14, 2022: Name of Director Resignation/Appointment: Mr. Manish Gupta (DIN: 06805265) Resigned as a Managing Director and Chief Executive Officer (MD & CEO) of the Company with effect from April 10, 2022. Mr. Rajaram Narayanan (DIN: 02977405) Appointed as MD & CEO of the Company for a period of 5 years, with effect from April 11, 2022. The appointment is subject to the approval of shareholders of the Company, which shall be sought separately.
14-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Shareholding for the Period Ended December 31, 2021

Sequent Scientific Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
13-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Statement Of Investor Complaints For The Quarter Ended December 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Krunal ShahDesignation :- Company Secretary and Compliance Officer
12-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Acquisition

With respect to the captioned subject, please find attached herewith the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. A press being issued by the Company is also attached herewith. We request you to take the above on your record.
12-01-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Acquisition

We wish to inform you that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Saude e Nutricao Animal Ltda ('Nourrie'). In this regard, please find attached: a. Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 b. A Press Release issued by the Company along with an Investor Presentation on the proposed acquisition We request you to take the above on record.
16-12-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Infinity Holdings
13-12-2021
Next Page
Close

Let's Open Free Demat Account